Marc Phillpotts, MD
Rheumatology · Temecula, CANPI 1518300151
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Amgen at 27.1% of the total. Reporting peaked in 2022 at $1,125 and has fallen 74.8% since, to $283 in 2025.
Across 129 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$892
- AbbVie$690
- UCB, Inc.$332
- GSK$239
- Novartis$221
- Lilly USA, LLC$203
- plus $710 from 11 others
What the payments were for
- Food & beverage$3,24099%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 28 | $892 |
| AbbVie | 31 | $690 |
| UCB, Inc. | 12 | $332 |
| GSK | 12 | $239 |
| Novartis | 11 | $221 |
| Lilly USA, LLC | 8 | $203 |
| Johnson & Johnson(2 entities) | 7 | $168 |
| Pfizer | 7 | $163 |
| Sanofi | 1 | $119 |
| Aurinia Pharma U.S., Inc. | 4 | $112 |
| Boehringer Ingelheim | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,286 in reported general payments places this provider in the 55th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 21 | $148,686 |
| MethotrexateMethotrexate Sodium | 30 | $1,786 |
| Colchicine | 12 | $1,595 |
| Leflunomide | 14 | $1,387 |
| Celecoxib | 20 | $1,208 |
| Prednisone | 79 | $645 |
| Hydroxychloroquine Sulfate | 12 | $637 |
| Alendronate Sodium | 33 | $361 |
| Duloxetine Hcl | 12 | $259 |
| Methylprednisolone | 20 | $169 |
| Meloxicam | 12 | $118 |
| Allopurinol | 14 | $107 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Temecula
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.